Skip to main content

NHGRI to Fund Small Molecule HTS with $4M in '09

NEW YORK (GenomeWeb News) – The National Institutes of Health will support researchers developing small molecule high throughput screening technologies that are more efficient than current systems with a total of $4 million in 2009.
 
These grants are part of an NIH program focused on expanding academic access to high throughput screening for identifying small molecule probes to interrogate the biology of novel targets, cell phenotypes, and pathways associated with disease processes.
 
The National Human Genome Research Institute and the National Institute of Mental Health will administer a total of up to $500,000 in direct expenses per year over two years to between five and seven investigators. NIH also is encouraging these researchers to utilize one of the centers within the Molecular Libraries Probe Production Centers Network (MLPCN) for installing and testing the instruments and to implement one or more screens. The MLPCN is part of the NIH Molecular Libraries and Imaging Roadmap Program.
 
This funding program includes two goals: one focused on late-stage development of technology and another on implementing and beta-testing high throughput screens of synthetic chemical and natural product libraries. These programs could include research aimed at creating improved cell and organism-based high content assay technologies, label-free assay instrumentation that use mass spectrometry, and other technologies.
 
NIH also will welcome applications for novel approaches to high throughput screening integration, microfluidics and lab-on-chip technologies, and methods for highly parallel ligand and target binding detection.
 
Letters of intent are due by September 2. More information may be found on the NIH’s website.
 
 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.